In summary, the present study uncovered the distinct methylation-transcription characteristics of “EGFR Wild Type/Low PD-L1 expression” NSCLC, and provided an adaptable way to identify potential therapeutic targets, which may enrich the library of candidates for combination strategies based on immune checkpoint inhibitors against this intractable lung cancer subtype. This evidence concerns the gene EGFR and lung cancer.